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Background: Children born with congenital anomalies present a very high rate of perinatal death and neonatal
mortality. Cytogenetic analysis is a convincing investigation along with clinical suspicion and biochemical screening
tests. The current study was designed to characterize the prevalence and types of chromosomal abnormalities in
high risk prenatal samples using different cytogenetic techniques.
Methods: This study was conducted on a total of 1,728 prenatal samples (1,324 amniotic fluids, 366 chorionic villi and
38 cord blood samples) from 1994 to 2014 at Institute of Human Genetics, Ahmedabad, India. Conventional karyotyping
was conducted with GTG-banding. Molecular approaches were used (fluorescence in situ hybridization = FISH and/ or
array-comparative genomic hybridization = aCGH) when indicated to detect karyotypic abnormalities.
Results: Abnormal karyotypes were detected in 125/1,728 (7.2%) cases. Trisomy 21 was the most common abnormality
detected in 46 (2.7%) followed by trisomy 18 in 11 (0.6%) and trisomy 13 in 2 (0.1%) samples. Besides, structural
abnormalities such as reciprocal and Robertsonian translocation were detected in 20 [1.2%] cases. Turner syndrome was
diagnosed in seven (0.4%) cases; in six (0.34%) cases there was an inversion in the Y-chromosome. Heteromorphic variants
were diagnosed in 22 (1.3%) cases. Finally, small supernumerary marker chromosomes (sSMC) were found in six (0.34%)
cases.
Conclusion: Conventional GTG-banding along with molecular cytogenetic techniques is useful in detecting genomic
alterations and rearrangements. Comprehensive characterization of chromosomal rearrangements like sSMC has
the potential to save potentially healthy fetuses from being terminated.
Keywords: Karyotyping, GTG-banding, Fluorescence in situ hybridization (FISH), Array-comparative genomic
hybridization (aCGH), Cell free DNA in maternal circulation (cfDNA), Chromosomal abnormalities, Prenatal samplesBackground
Naturally, the most expressed desire of a couple is to
have a physically and mentally healthy baby after being
pregnant. Obviously, any screening program that aims to
provide contributions for such an assurance will cause
anxiety while waiting for the test results. False positive
screening tests in sonography and/or maternal serum
screening and lack of therapeutic options for chromo-
somal abnormalities will cause additional problems. It is
therefore important to select appropriate screening tests
and diagnostic procedures that are precise, accurate, safe* Correspondence: fshethad1@googlemail.com
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unless otherwise stated.and can be performed during early pregnancy to achieve
the most meaningful decision considering the potential
outcome of pregnancy. Approximately 2.5% of infants
are born with congenital anomalies; accounted for 8-
15% of perinatal deaths and 13-16% of the neonatal
mortality in India. Chromosomal anomalies are de-
tected in 6% of them [1,2]. The most common
chromosomal abnormalities are numerical ones of the
sex chromosome and for the autosomes (trisomies 21,
18 and 13). While point mutation rate is slightly
higher in sperms of older fathers; the risk for trisomies
is significantly increased with advanced maternal age.
Average maternal age at child bearing has increased
throughout the world; also the prenatal diagnostichis is an Open Access article distributed under the terms of the Creative
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make a decision on the fate of pregnancy [3].
Among the prenatal screening tests, ultrasonography is
the simplest available non-invasive method for detection
of abnormal embryogenesis (increased nuchal translu-
cency, double bubble sign, duodenal atresia, spina bifida
etc.). Double marker [pregnancy-associated plasma pro-
tein A (PAPP-A) and free ß-HCG (human chorionic go-
nadotropin)], triple marker [α-feto protein (AFP), free
βHCG, unconjugated estriol (μE)] and/or quadruple
marker screens [4] on maternal serum or in combination
with ultrasonography can be applied to identify fetuses at
risk of autosomal aneuploidies, particularly trisomies 21,
18, 13. They are still only ‘risk-determination-tests’ as a
definite chromosomal diagnosis can be made only from
the fetal cells. Fetal cells can be safely obtained from amni-
otic fluid (AF), chorionic villus sampling (CVS) or cordo-
centesis (CB) and can be used for precise and accurate
prenatal diagnosis [5].
Second trimester studies of AF are performed at about
16 weeks’ of gestation without significant technical diffi-
culties. However, alternative options include CVS at 11-
13 weeks’ and early amniocentesis [6]. Very recently,
fetal cells can be studied from maternal blood, more pre-
cisely from fetal DNA in maternal circulation (cfDNA)
with a limitation of detecting most common aneuploidy
like trisomy 21, 18, 13 only [7]. Similarly, alteration at
the submicroscopic level across the genome can be studied
using array Comparative Genomic Hybridization (aCGH)
from fetal DNA [8].
The aim of the present study was to assess the preva-
lence and types of chromosomal abnormalities in cases
where ultrasonography and biochemical markers were
positive, advance maternal age or history of genetic dis-
orders in the family were reasons for fetal cell acquisi-
tion. The samples were collected over a period of
20 years in Gujarat, Western India and primarily studied
by conventional banding cytogenetics. Moreover, the ad-
vantages and limitation of various molecular cytogenetic
techniques in detecting genomic rearrangements are
discussed.
Methods
This retrospective observational cross-sectional study
was carried out at Institute of Human Genetics for the
period between 1994 and 2014. A total of 1,728 prenatal
samples (cases) were included in the study [amniotic
fluid (n = 1324), chorionic villus (n = 366) and cord
blood (n = 38)]. The patients were adequately counseled
regarding prenatal diagnosis after obtaining family and
gestation history. Signed informed consent was obtained
as per Helsinki declaration for utilization of the patient
information and data for academic purposes including
research publications. Approval to carry out the studywas acquired from FRIGE institutional ethics commit-
tee. Amongst the 1,728 cases investigated, 892 prenatal
cases were positive in biochemical screen, 227 were
positive for soft markers through ultrasonography, 559
cases presented with advanced maternal age, and 50
cases provided a history of previous children with gen-
etic disorders.
After receiving the samples, they were processed as
per the standard protocol of GTG-banding to determine
the karyotype. Fluorescence in situ hybridization (FISH)
and/ or array-comparative genomic hybridization
(aCGH) studies were carried out following standard
approaches as and when indicated.Results
The mean age of all participating women was
31.6 years (range: 19 to 53 years). Chromosomal ab-
normalities were detected in 125 (7.2%) cases. Most
likely disease causing chromosomal abnormalities was
found in 103 (6%) cases and heteromorphic variants
were detected in 22 (1.3%) cases. The distribution of
chromosomal abnormalities detected in different
samples is shown in Figure 1. Chromosomal alter-
ations in respect to various risk factors are depicted
in Table 1. Among 125 cases of chromosomal anom-
alies, 50 (40%) cases had positive biochemical marker
screen test, 17 (13.6%) cases were studied due to
advanced maternal age, 32 (25.6%) cases were associ-
ated with positive soft markers and 26 (20.8%)
cases had previous history of children with genetic
disorders.
Table 2 shows the summary of the chromosomal
aberrations detected. The most common numerical
alteration diagnosed was trisomy 21 (46/1728; 2.7%),
followed by trisomy 18 (11/1728; 0.6%), monosomy X
(7/1728; 0.4%) and trisomy 13 (2/1728; 0.1%); trip-
loidy and tetraploidy were detected in one case, each.
Finally structural anomalies were detected in 2.02%
(35/1728) and heteromorphic variants in 1.3% (22/
1728) of the cases (Table 2).
Mosaics were initially detected in four cases but
further examination of second samples later during
pregnancies or at birth revealed normal karyotypes,
hence these cases were considered as normal. Six
(0.34%) carriers of sSMC were detected and in four
cases parents declined further analysis and opted for
immediate termination of pregnancy. Hence, precise
characterization of sSMC was carried out only in two
cases (Table 2).
Selected cases are described below. They demon-
strate importance of karyotyping and molecular cyto-
genetics followed by genetic counseling to provide a
good care for pregnant women.
Figure 1 Number of cases (both normal and abnormal) in different prenatal samples.
Table 1 Distribution of chromosomal abnormalities with respect to risk factors (n = 125)










AMA 5 - 2 2 - 1 2 1
TMS positive 23 3 2 - - 1 2 4
soft marker positive 17 1 3 - - - - 6
H/O of genetic
disease
4 2 2 4 - - 1 5
chorion
(n = 29)
AMA 1 - 1 - 1 - 1 -
TMS positive 10 - 1 - - - - 2
soft marker positive 4 - - - - - - -
H/O of genetic
disorder
2 2 1 - - - - 3
cord blood
(n = 3)
AMA - - - - - - - -
TMS positive 1 - - - - - - 1
soft marker positive 1 - - - - - -
H/O of genetic
disease
- - - - - - - -
AMA = advanced maternal age; H/O = history of; TMS = triple marker study.
Sheth et al. BMC Pregnancy and Childbirth  (2015) 15:90 Page 3 of 7
Table 2 Summary of chromosomal aberrations (n = 125)
Chromosomal abnormalities Number










structural anomalies (n = 57)


















deletion (n = 2) 46,XN,der(X),del(X)p11 1
46,XN,del(16)(q13;q22) 1
sSMC (n = 6) 47,XN,+mar.ish inv dup(Y)(pter- > Yp11.2::Yp11.2- > pter) 1
48,XN,+inv dup(13 or 21)(q10),+del(13 or 21)(q10) 1
47,XN,+mar 2**
46,XN/47,XN,+mar 2**
isochromosome (n = 1) 46,XN,i(X)(q10) 1
inversion (n = 6) 46,X,inv(Y) 6
variant (n = 22) Satellite and heterochromatic polymorphism 22
* Four cases initially showed chromosomal aberrations and later on found as normal in second sample, hence they are not included the study as abnormal.
** Parents opted for termination and no further characterization was done.
*** Patient declined for further analysis.
# Detail history in case 8.
@ Except 46,XN,t(2;20)(q23;q13.1) all the translocations were derived from one of the parents.
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The triple marker screen in a 30 year-old female was
1:3,000 for trisomy 21 with an age related risk for aneu-
ploidy of 1:700. Considering individual screening
markers, there was the following observation; β-HCG =
0.7 MoM; μE = 0.7 MoM; AFP = 1.0 MoM. The amniotic
fluid study was then conducted in view of a possibility
for cytogenetic anomaly [4]. Interphase-FISH (I-FISH)
on uncultivated amniocytes excluded trisomies for chro-
mosomes 13, 18 and 21. Chromosomes derived from
cultured amniotic cells revealed a karyotype 46,X,i(X)
(q10). This demonstrates that structural abnormality can
also be present in triple marker screen and I-FISH nega-
tive cases. Thus interpretation of individual biochemical
parameters is important and one should not depend only
on software based risk calculations.
Case 2
Amniotic fluid cells from a 38 year old female were ana-
lyzed as triple marker screen showed an increased risk
for trisomy 21 (1:200) with AFP = 2.3 MoM, β-HCG =
2.0 MoM and μE = 0.8 MoM. The age related risk for
aneuploidy was 1:150. I-FISH in uncultivated amniocytes
excluded trisomies for chromosomes 13 and 21.
Chromosome analysis from cultivated amniotic cells
showed a karyotype 46,X,del(X)(p11). This demonstrates
that structural abnormality can be present in triple
marker screen positive and I-FISH negative cases. It in-
dicates that I-FISH should be used only to relieve pa-
tient’s anxiety and not as a single confirmatory test; a
confirmation is to be sought by comprehensive chromo-
somal studies from cultivated cells.
Cases 3 to 5
Three pregnant women with an age range of 22 to
30 years were referred for karyotype studies from AF
due to fetal anomalies detected in ultrasonography dur-
ing late second or mid third trimester. Different soft
markers like double bubble sign and hyperechoic lesions
in both the ventricles or in one each, while duodenal
atresia and limb abnormalities was detected only in one
case. Triple marker screening test was not carried out in
any of these cases. Chromosomal analysis from AF in
these three cases revealed trisomy 21, 13 or 18 respect-
ively which could have been detected quite early if
double or triple marker screening test would have been
carried out.
Case 6
Prenatal study was advised to an elderly couple during
primi gravida. Kayotype analysis was carried out from
AF that showed the presence of two de novo sSMCs;
karyotype 48,XN,+mar1,+mar2[100%]. Triple marker
study carried out at 16 weeks of gestation did not showany enhanced risk for trisomy 13, 18 and 21. Fetal
anomaly scan carried out at 16 and 24 weeks were nor-
mal. After application of FISH probes developed for
sSMC-characterization described elsewhere [9]; the
sSMCs were characterized as inv dup(13 or 21)(q10) and
del(13 or 21)(q10). As the sSMCs were exclusively made
up of heterochromatic material they were unlikely to be
associated with any clinical abnormalities. Most likely,
the sSMC are derived from each other. Advanced mater-
nal age was most often associated with sSMC derived
from #13/21 and in majority of cases, no dysmorphism
was detected after birth. The pregnancy in the patient
therefore was continued and resulted in the delivery of a
normal healthy child.
Case 7
Prenatal diagnosis was offered during third gravida to a
young couple. They had a previous child with free
trisomy for chromosome 21 [Down syndrome] and
her second pregnancy ended in a first trimester mis-
carriage. Fetal karyotype obtained from AF revealed
presence of a ‘de novo’ sSMC in all cells with normal
sex chromosomes karyotype: 47,XN,+mar[100%] as
parental chromosomal study was normal [Figure 2].
Detailed molecular cytogenetic characterization was
carried out with the final karyotype 47,XN,+mar.ish
inv dup(Y)(pter- > Yp11.2::Yp11.2- > pter)(SRY++)(subtelX/
Y++). Thus, a neocentric sSMC formation was observed.
This case showed repeated aneuploidy and the sSMC
would have been missed if only I-FISH test was carried out.
Case 8
A young non-consanguineous couple had two first tri-
mester fetal losses and two children with congenital
anomalies and mental retardation of varying degrees.
Chromosome analysis of both the sibs (7 yrs and 5 yrs)
was normal at 550 band resolution. During 5th gravid-
ity, a CVS sample was processed for cytogenetic study.
It revealed a Robersonian translocation involving chro-
mosomes 13 and 14 inherited from the phenotypically
normal father. Array Comparative Genomic Hybridization
(aCGH) analysis showed 151-283 kb deletion inside
LINGO2 (LRRN6C) gene on 9p21.1 in the affected sibs, in
CVS and the father. Since the father was phenotypically
normal, this deletion is most likely a CNV (copy number
variant) without phenotypic effects. Even though all the
analyses were normal, parents opted for termination of
pregnancy due to array report.
Discussion
Data derived from population-based congenital anomaly
registries show that many fetal miscarriages or intrauterine
death are due to chromosomal abnormalities in the first
trimester of pregnancy; being detected as a consequence
Figure 2 Karyotype of case 7 showed presence of sSMC in addition to normal 46 chromosomes.
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chromosomal anomalies were detected in 125 (7.2%) pre-
natal samples. This high number of chromosomal abnor-
malities in our study is likely to be due to a selection bias
of investigating only highly suspected referral cases with
possible chromosomal abnormalities. This rate therefore
was higher than that found in consecutive unselected new-
born studies (e.g. 0.262 per 100 cases) [11,12]. The 7.2%
abnormal cases that were classified as rare microscopically
visible chromosomal abnormalities (such as deletions, tri-
somies, unbalanced translocation, markers, mosaicism and
apparently balanced rearrangements) are much lower than
the study reported by Baena et al. [13].
In all recognized conceptions, triploidy is estimated to
follow in 1–2% [14] with a miscarriage rate of 33% be-
fore 15 weeks of gestation. In this study one tetraploidy
and tripoloidy each was detected during second
trimester.
sSMCs were found in six (0.4%) cases in the current
study. Liehr and Wiese reviewed 132 studies on sSMC
with an average prevalence rate of 7.5/10,000 births [15].
The prevalence rate in the present study was higher
which most probably was due to selection of only refer-
ral cases as well as smaller sample size. Both cases were
comprehensively characterized further by molecular
cytogenetics. If aCGH would not have been used, case 7
would have been missed as only presence of heterochro-
matin on the sSMCs.
Chromosomal deletions in prenatal samples are rare
[16,17] as well. Congenital anomaly register data showed
the prevalence of microscopically visible deletions in the
range of 0.3 to 2/10,000 births [18-20]. In the present
study, only two such cases were found. Overall, it is diffi-
cult to find out the prevalence rates in a country likeIndia where the rate of illiteracy is high with less priority
to health issues.
In summary, 3.4% cases were detected with trisomies
of chromosomes 13, 18 or 21 (59/1,728) while in 3.7%
cases, other chromosomal rearrangements were present.
As fetal loss is the most common fear among women
while undergoing invasive prenatal procedure, recent de-
tection of cfDNA is a promising technique; offering the
possibility to detect fetal numerical chromosomal aber-
rations in a non-invasive way [21]. In invasive prenatal
diagnosis, another relatively new investigative tool with
genome wide coverage (aCGH) and high resolution at
molecular level revolutionized cytogenetics [22]. In the
present study, 20 translocations (12 reciprocal and 8
Robertsonian ones) were detected. Apparently balanced
translocation was observed in all these cases and no dys-
morphism was detected after birth except in three cases
(trisomy 21). These genomic rearrangements [i.e. der
(13;14)] would have been missed by aCGH or noninva-
sive technique of fetal blood in maternal circulation
(cfDNA) as shown in case 8. Nonetheless, aCGH in-
creases the detection rate of genomic imbalances by
2.9% over conventional karyotyping [23]. However,
chromosomal microarray in prenatal testing cannot sub-
stitute conventional karyotyping as a tool for general
screening in all pregnancies. ACOG committee [8] how-
ever, recommends chromosomal microarray in patients
undergoing invasive prenatal diagnosis and this test re-
places the need for fetal karyotype when structural
anomalies are detected under ultrasonography examin-
ation. Secondly, a genetic mutations identified by
chromosome microarray study is not confined to ad-
vanced maternal age. In India, the availability of
chromosomal microarray is very limited and expensive.
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centers offering this test. Fetal karyotype from the samples
obtained by invasive methods therefore still continues to be
a widely accepted modality in such cases. The need for pre-
test and post-test genetic counseling from qualified
personnel has to be strictly followed [8]. However, looking
to our data, nearly 50% cases would have been missed using
this technology only, which indicates that karyotype studies
from CVS or AF are the gold standard; patients should
therefore be counseled and informed about the advantage
and limitation of aCGH and non-invasive technologies. By
detecting abnormal karyotypes during prenatal period, it is
possible to reduce the rate of chromosomal abnormalities
among the populations of a country; thereby reducing so-
cial as well as family trauma and financial burden due to
disabled children. It must still be an individual decision of
the pregnant woman and her partner if they decide for or
against a child with a known chromosomal abnormality.
The society also has to accept and support decisions for
disabled children due to religious or other reasons as abor-
tions are also known to cause trauma to the affected
woman.
Conclusion
In the era of aCGH and next generation sequencing, con-
ventional karyotyping maintains its role as a diagnostic tool
in detecting gross chromosomal alterations and rearrange-
ments. However, in the cases of sSMCs, molecular tech-
niques further complement in characterizing chromosomal
rearrangements that can save potentially healthy fetuses
from being terminated. Additionally, cryptic imbalances
can be detected with aCGH when structural anomalies are
detected during an antenatal ultrasonography examination.
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